SEC Filing Summary for Can-Fite BioPharma Ltd. - Officer/Director Change

This filing details a Form 3, Initial Statement of Beneficial Ownership, for Ilan Tamir, a director at Can-Fite BioPharma Ltd. The report, dated March 18, 2026, indicates that Tamir holds options to purchase 16,000 ordinary shares. These options are not currently vested and will vest in sixteen equal quarterly installments starting April 25, 2026, and ending January 25, 2030, contingent upon Tamir's continued service. The exercise price for these options is $2.25, originally denominated in New Israeli Shekels and converted to USD using the exchange rate from April 20, 2026. The securities are registered in a trustee's name to comply with Israeli tax benefits under specific share option plans.